Fig. 3

Lesion based analysis (PET-positive local recurrence/primary tumour and PET-positive lymph node and distant metastases) according to sub-grouping of patients (patients before definitive RT at initial diagnosis, patients before salvage RT with PSA recurrence, patients before Salvage RT with PSA < 0.5 ng/ml, patients before additive RT with PSA persistence, patients before additive RT with PSA persistence with PSA < 0.5 ng/ml)